7 WHO Policy Perspectives on Medicines

First Page		Document Content
Date: 2003-11-04 03:20:21 Pharmaceuticals policy Health Drug safety Pharmaceutical industry Essential medicines Regulation of therapeutic goods Counterfeit medications Therapeutic Goods Administration Department of Essential Drugs and Medicines Pharmaceutical sciences Pharmacy Pharmacology		7 WHO Policy Perspectives on Medicines Add to Reading List Source URL: whqlibdoc.who.int Download Document from Source Website File Size: 139,00 KB Share Document on Facebook

	IMDRF Presentation: Jurisdictional update - Australia DocID: 1paZs - View Document
	Appendix B.10 Department of Health Summary Health reported 59 measures during the year, with a total net regulatory saving of $96.8 million per year. In 2015, the Health Portfolio continued to contribute strongly to th DocID: 1oUqD - View Document
	2015 Annual Red Tape Reduction Report Appendix B.10 - Department of Health DocID: 1oH8C - View Document
	The Australian and New Zealand Medical Device Incident Report Investigation Scheme What is it? The Scheme is a joint venture between the Australian Therapeutic Goods Administration and Medsafe, the New Zealand Medicines DocID: 1lTjb - View Document
	AUSTRALIAN GOVERNMENT WARNINGS & OTHER ACTIONS ON PSYCHOTROPIC DRUGS The Therapeutic Goods Administration (TGA) is Australia’s drug regulatory agency. They are responsible for authorising the sale of drugs and medical DocID: 1jYXQ - View Document